Roche’s personalised cancer treatment wins FDA approval
The treatment, Rozlytrek, is a tyrosine kinase inhibitor that targets patients who must be identified via genetic profiling
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.